OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma	2745
Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma	2482
Hemophagocytic Lymphohistiocytosis Clinical Features and Outcomes: Single Institution Case Series	1378
Development of a Fast and Quantitative FLT3-TKD Mutation Prototype Using Lab in a Cartridge™ Technology	354
SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86	297
Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients	228
Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML	225
Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma	221
Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma	203
A-two to the rescue	200
Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203-215.	197
Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance	193
The chromatin accessibility landscape of pediatric AML	190
A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)	187
Contactless edema via plasmin	186
Waking up exhausted BCMA-specific T cells in myeloma	172
Heparin or nonheparin anticoagulants for VITT	165
MDM2 inhibition augments GVL effect	159
Blast phagocytosis	153
Unexpected parvovirus B19 infection in a patient with multiple myeloma	148
Bleeding tendency with corkscrew hair	146
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria	145
PI3king apart a rare disease with targeted therapy	145
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy	144
Breaking T-cell tolerance in the immune system	143

Targeting PKCα decreases iron overload in diabetes	141
C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis	140
A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders	140
Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma	138
The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway	138
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience	132
Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology	132
Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide	131
Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study	130
The Role of N-Acetylcysteine Amide (NACA) As Prophylactic Treatment for Acute Graft-Versus-Host Disease	128
Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?	128
Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy	126
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study	125
Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma	124
Antiviral Response and HIV-1 Inhibition in Sickle Cell Disease	123
Profiling the E3 Ubiquitin Ligase Landscape in Normal and Sickle Red Blood Cells	121
White Matter Injury in Sickle Cell Mice Is Associated with Reduced Neurocognitive Function and Activation of Astrocytes	120
Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy	119
Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study	119
A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation	117
Perception of Marijuana Use, Risk/Benefits in Sickle Cell Disease	117
Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems	116
No Specific Factors Associated with Risk of Readmission for Rebound Pain in Children with Sickle Cell Disease and Asthma Treated with Systemic Corticosteroids	113
Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib	112
Suppressed Expression of ASCT1 Contributes to the Maintenance of Leukemia Stemness Via the Enhancement of Antioxidant Capacity	109
Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma	109
Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents	107
Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population	106
P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion	105
Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry	103
Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels	103
The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma	102
Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets	101
Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial	100
Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination	97
Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Ther	95
Analysis of Liquid Biopsy Performance for the Detection of Lymphoma in Dogs with a Focus on Recurrent Copy Number Variants in Matched Plasma and Lymph Node Aspirates: Implications for a Comparative On	94
Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo	94
Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients	93
Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in Primary and Secondary Brain Cancers: An up-to-Date Meta-Analysis of Comparative St	93
Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country	92
Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma	91
Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis	91
The Profiling of Circulating Tumor DNA Liquid Biopsy in Children and Adolescent Lymphoblastic Lymphoma	91
Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell	90
Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes	90
CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells	89
Empagliflozin Modifies Neutrophils' Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils	89
The Expression of SREBF1 Inducing By Dexamethasone Promotes Bone Marrow Mesenchymal Stromal Cells Differentiate to Adipocytes to Attract and Protect the Residual T-Cell Acute Lymphoblastic Leukemia Ce	89
Cellular Therapy Product Viability during Long Term Cryopreserved Storage	89

Values and Preferences Towards Antithrombotic Therapy in Patients with Myeloproliferative Neoplasms: A Qualitative Study	87
Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation	87
Interim PET-CT Scan to Improve Risk Modeling for Patients with Extranodal Natural Killer/T-Cell Lymphoma Treated with Non-Anthracycline Containing L-Asparaginase Based Regimen	87
Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects	87
Identification of Biomarkers As Predictors of Patient-Reported Outcomes in Persons with Multiple Sclerosis Given Autologous Hematopoietic Stem Cell Transplantation	86
A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic	83
Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry	83
Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group	83